Patients and methods

PATIENTS AND CONTROLS
Blood was collected from 13 female patients fulfilling the revised American Rheumatism Association criteria for SLE.6 At the time of the study five of the patients were regarded as clinically active and were being treated with prednisolone (5-20 mg/day) with, in three instances, azathioprine (150 mg). Other patients were in receipt of non-steroidal antiinflammatory agents.
Normal females (nine) and males (eight) were members of staff at St Mary's Hospital Medical School.
Blood was taken into heparin (10 IU/ml of blood), and the separated plasma was stored at -20°C. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) FOR ANTIBODIES TO DNA ELISA assays were developed for determining antibodies to native and denatured DNA. The assays were carried out in flat-bottom microtitre plates (M29AR, Sterilin) and, unless otherwise stated, additions to the wells were in 60 tl volumes, incubations were for 1 h in a 37°C water bath, and washing between each assay step was with phosphate-buffered saline (PBS) containing 0-05% (v/v) Tween 20 (Sigma).
DNA preparations for coating the wells were obtained as follows. Native DNA (nDNA) from calf thymus (D1501, Sigma) was dissolved at 1 g/l in citrate buffer at pH 8 (0-15 M sodium chloride; 0-015 M sodium citrate). Denatured DNA (dDNA) was prepared by immersing a sample of this stock solution in a boiling water bath for 15 min before plunging it into an ice bath. DNA Plates were coated with nDNA and dDNA as described above, and these same preparations were used for inhibition. Also used in the inhibition was an Escherichia coli plasmid (pAT153 containing a 1-9 kb BamHl fragment of human 0-globin) referred to as nDNA-P. This highly purified preparation of nDNA was in circular form-90% supercoil and 10% relaxed-and contained no .0z8 Plasma samples from normal males, normal < 0 females, and SLE patients were assayed for IgG and C 8 IgM antibodies to nDNA in the ELISA system (Fig. X 8 . There was no correlation between Farr and ELISA in the normal females (IgG, r=-0-18; IgM, r= +0-21).
SPECIFICITY OF ANTIBODIES TO DNA
The specificity of the antibodies detected in the ELISA assays for anti-nDNA and anti-dDNA was (Fig. 8 ).
Discussion
The ELISA for IgG antibodies to nDNA gave results in SLE patients which correlated strongly with those obtained by the standard Farr test. Indeed it was more successful than Farr in differentiating between patients and normal donors. Although detailed analysis of this data according to disease activity is not appropriate, it was noted that only one out of seven samples negative by ELISA (<20 EU) came from a patient considered clinically active, whereas only one of five registering over 60 units was from an 'inactive' donor.
In marked contrast the ELISA results for IgM antibodies to nDNA showed no correlation with Farr, and it must be concluded that the latter test did not provide a satisfactory assay for such antibodies. The high salt concentration used for precipitation of bound antigen in the Farr test may give rise to preferential dissociation of IgM because of the generally lower affinity of its binding sites and the apparent tendency of IgG to engage in highly stable bivalent bonding to single DNA molecules. Other groups have shown similar strong correlation between ELISA and Farr for IgG anti-nDNA; for IgM significant correlations were obtained but these were notably weaker than for IgG.9 10 The lack of correlation between 1gM anti-DNA and Farr observed in the present system emphasises the possibility of obtaining useful information by simultaneous measurement of both IgG be due, therefore, to cross reactions between the deoxyribose-phosphate backbone on double-and single-stranded molecules. The enhanced potency at lower concentrations of dDNA as compared with nDNA could result from the greater flexibility of the single-stranded molecule which increases the opportunity for the highly avid bivalent bonding to single molecules. 4 13 In the assay for antibodies to dDNA, on the other hand, dDNA was a much more effective inhibitor than were the preparations of nDNA. What then had become of the antibodies which had been shown in the 'native' assay to bind to both nDNA and dDNA? The conclusion must be drawn that such antibodies form a minor group in comparison with those directed against determinants which are specific for the single strand, presumably the base-related determinants, which are not exposed in nDNA. Antibodies to nucleosides are known to occur in SLE, though their quantitative relationship to other anti-DNA antibodies is not clear. 14 In mouse SLE, however, they do appear to form the bulk of the antibodies against dDNA. 15 Such a swamping effect may be less marked for IgM, which was relatively more sensitive to inhibition by nDNA.
Specificity of ELISA for antibodies to DNA has also been investigated by other groups, though they did not include a study of IgM antibodies or employ an inhibitor preparation comparable in definition to nDNA-P. 1618 The results for IgG or combined classes were in general agreement with those presented here, but considerable variation in the behaviour of individual sera was observed. For example, some sera showed greater potency of nDNA than dDNA in the inhibition of the 'native' assay. 18 Moderately high levels of IgM anti-DNA were found in some normal females, and this may be related to the higher levels of total IgM seen in females as compared with males.19 The differences observed between normal males and females for IgG are difficult to interpret, since the low ELISA values obtained may well represent non-specific interaction between immunoglobulin and DNA. In the Farr assay binding up to 30% is seen with normal samples, and this must be of high affinity, though not necessarily involving immunoglobulin.3 Our ELISA results for normal females did not appear to correlate with Farr, and the whole question of normal levels of anti-DNA antibodies requires further investigation.
In seems then that the ELISA system described fulfils the requirements for an assay of antibodies to DNA set out at the beginning of this paper. Further tests (data not shown) have provided no evidence of interference in the assay by plasma rheumatoid factors (see also ref. 10) . Particular advantages of the system are that specificity. is obtained without the need for highly purified DNA preparations and that the antigen is applied directly to the microtitre plate without a precoating step.20 The ELISA system is now being tested further to assess its value in both the diagnosis and monitoring of SLE and other diseases. This book is an invaluable source of references to clinical trials reported up to 1983, and the associated comments on methodology should be read by anyone planning to undertake a trial in the rheumatic diseases. The source of antibodies was pooled plasma from patients with systemic lupus erythematosus. The figure was previously printed without the triangle point at 100 ig/ml which demonstrates a high level of inhibition by dDNA. 
